Report cover image

Type II DNA topoisomerase inhibitors - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 85 Pages
SKU # DEL19993761

Description

DelveInsight’s, “Type II DNA topoisomerase inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Type II DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Type II DNA topoisomerase inhibitors Understanding

Type II DNA topoisomerase inhibitors: Overview

Type II topoisomerases are ubiquitous enzymes that play an essential role in the control of replicative DNA synthesis and share structural and functional homology among different prokaryotic and eukaryotic organisms. Small molecules that target type II topoisomerase are divided into two classes: inhibitors and poisons. Due to their frequent presence in proliferating eukaryotic cells, inhibitors of type II topoisomerases have been extensively studied and used as anti-cancer medications.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Type II DNA topoisomerase inhibitors R&D. The therapies under development are focused on novel approaches for Type II DNA topoisomerase inhibitors.
Type II DNA topoisomerase inhibitors Emerging Drugs Chapters

This segment of the Type II DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type II DNA topoisomerase inhibitors Emerging Drugs
  • TRP-1001: Tryp Therapeutics
Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Currently, it is in Phase II stage of development to treat soft tissue sarcoma.
  • Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
A liposomal formulation of mitoxantrone is being developed by CSPC ZhongQi Pharmaceutical Technology, for the treatment of solid tumours and lymphoma. Currently, it is in preregistration stage of development to treat Peripheral T-cell lymphoma.

Further product details are provided in the report……..

Type II DNA topoisomerase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Type II DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Type II DNA topoisomerase inhibitors
There are approx. 30+ key companies which are developing the Type II DNA topoisomerase inhibitors. The companies which have their Type II DNA topoisomerase inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, CSPC ZhongQi Pharmaceutical Technology.
  • Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Type II DNA topoisomerase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type II DNA topoisomerase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type II DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type II DNA topoisomerase inhibitors drugs.

Type II DNA topoisomerase inhibitors Report Insights
  • Type II DNA topoisomerase inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Type II DNA topoisomerase inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Type II DNA topoisomerase inhibitors drugs?
  • How many Type II DNA topoisomerase inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type II DNA topoisomerase inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type II DNA topoisomerase inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Type II DNA topoisomerase inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Tryp Therapeutics
  • CSPC ZhongQi Pharmaceutical Technology
  • Oasmia Pharmaceutical
  • Aradigm
  • Teclison
  • Denovo Biopharma
  • NanoCarrier
  • EnGeneIC
  • Avacta
  • Shasqi
  • SkinJect
  • Lantern Pharma
  • Double Bond Pharmaceutical
  • POP Biotechnologies
  • LIDDS
  • TenNor Therapeutics
  • Exelixis
  • EnGeneIC
Key Products
  • TRP-1001
  • Mitoxantrone liposomal
  • Doxophos
  • Apulmiq
  • Tirazone
  • DB 106
  • NC 6003
  • VEDVDox
  • AVA 6000
  • SQ 3370
  • Doxorubicin-containing MNA
  • LP 184
  • SA 033
  • Doxorubicin/Porphyrin phospholipid nanoparticles
  • NZ DOX
  • PNU-159682 based antibody drug conjugate
  • E-EDV-D682


Please Note: It will take 3-4 business days to complete the report upon order confirmation.

Table of Contents

85 Pages
Introduction
Executive Summary
Type II DNA topoisomerase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Type II DNA topoisomerase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TRP-1001: Tryp Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
NC 6003: NanoCarrier
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NZ DOX: LIDDS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type II DNA topoisomerase inhibitors Key Companies
Type II DNA topoisomerase inhibitors Key Products
Type II DNA topoisomerase inhibitors- Unmet Needs
Type II DNA topoisomerase inhibitors- Market Drivers and Barriers
Type II DNA topoisomerase inhibitors- Future Perspectives and Conclusion
Type II DNA topoisomerase inhibitors Analyst Views
Type II DNA topoisomerase inhibitors Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us